Wallace J M, Case D B, Laragh J H, Sealey J E, Keim H J, Drayer J I
Trans Assoc Am Physicians. 1977;90:300-12.
(1) An immediate pressor response so saralasin, 10 microgram/kg/min, occurred in 52 of 57 (91%) hypertensive patients. (2) We propose that the amplitude of the immediate pressor response functions as an in vivo measure of the number of initially vacan angiotensin II vascular receptors. (3) The immediate pressor response to saralasin forecasts the subsequent sustained response, both of which are related to the renin-sodium profile. (4) The dual blood pressure responses to saralasin, immediate and sustained, make this drug useful for the pharmacological identification of high, normal, and low renin hypertensive patients as they are presently classified. (5) The ability of saralasin to elevate the BP immediately in most hypertensive patients shows the need for caution in its use. It is a safe drug from this standpoint if very small infusions (0.01-0.10 microgram/kg/min) are first tried in hypertensive patients whose PRA is unknown.
(1)57例高血压患者中有52例(91%)对每分钟10微克/千克的沙拉新出现了即刻升压反应。(2)我们提出,即刻升压反应的幅度可作为体内初始空缺的血管紧张素II血管受体数量的一种测量方法。(3)对沙拉新的即刻升压反应可预测随后的持续反应,这两种反应均与肾素-钠情况相关。(4)沙拉新引起的即刻和持续双重血压反应,使该药对于目前分类的高肾素、正常肾素和低肾素高血压患者的药理学鉴别很有用。(5)沙拉新能使大多数高血压患者的血压即刻升高,这表明使用该药时需谨慎。从这一角度来看,如果首先在血浆肾素活性未知的高血压患者中尝试非常小剂量的输注(0.01 - 0.10微克/千克/分钟),那么它是一种安全的药物。